ScoreWhy is Mayinglong Pharmaceutical Group Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 36.83%
- The company has been able to generate a Return on Capital Employed (avg) of 36.83% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 3.39% and Operating profit at 11.30% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 13.86% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 3.39% and Operating profit at 11.30% over the last 5 years
4
Flat results in Jun 26
- DEBT-EQUITY RATIO (HY) Highest at -51.37 %
- RAW MATERIAL COST(Y) Grown by 6.74% (YoY)
- DEBTORS TURNOVER RATIO(HY) Lowest at 5.19 times
5
With ROE of 13.52%, it has a attractive valuation with a 2.02 Price to Book Value
- Over the past year, while the stock has generated a return of -15.10%, its profits have risen by 11.4% ; the PEG ratio of the company is 1.3
- At the current price, the company has a high dividend yield of 2.9
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Mayinglong Pharmaceutical Group Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Mayinglong Pharmaceutical Group Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Mayinglong Pharmaceutical Group Co., Ltd.
-17.19%
-0.93
23.03%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.39%
EBIT Growth (5y)
11.30%
EBIT to Interest (avg)
55.59
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.82
Tax Ratio
14.36%
Dividend Payout Ratio
51.89%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
37.14%
ROE (avg)
13.86%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
2.02
EV to EBIT
10.53
EV to EBITDA
9.45
EV to Capital Employed
3.17
EV to Sales
1.76
PEG Ratio
1.32
Dividend Yield
2.88%
ROCE (Latest)
30.13%
ROE (Latest)
13.52%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
ROCE(HY)
Highest at 14%
INVENTORY TURNOVER RATIO(HY)
Highest at 7.62 times
-4What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -51.37 %
RAW MATERIAL COST(Y)
Grown by 6.74% (YoY
DEBTORS TURNOVER RATIO(HY)
Lowest at 5.19 times
Here's what is working for Mayinglong Pharmaceutical Group Co., Ltd.
Inventory Turnover Ratio
Highest at 7.62 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Mayinglong Pharmaceutical Group Co., Ltd.
Debt-Equity Ratio
Highest at -51.37 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Debtors Turnover Ratio
Lowest at 5.19 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
Raw Material Cost
Grown by 6.74% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
Footer loading
